AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15094256 — intervention group
Group type: EXPERIMENTAL
Intervention: EPDS score >9 at week 4 postpartum
Number of subjects: 50
Study 11510804 — intervention group
Group type: EXPERIMENTAL
Intervention: Keliximab 0.5 mg/kg
Number of subjects: 21
Study 11510804 — intervention group
Group type: EXPERIMENTAL
Intervention: Keliximab 1.5 mg/kg
Number of subjects: 21
Study 11510804 — intervention group
Group type: EXPERIMENTAL
Intervention: Keliximab 3.0 mg/kg
Number of subjects: 21
Study 11510804 — intervention group
Group type: EXPERIMENTAL
Intervention: Keliximab (all doses combined)
Number of subjects: 21
Study 11510804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9764780 — intervention group
Group type: EXPERIMENTAL
Intervention: pVL nadir < or = 20 copies/ml
Number of subjects: 104
Study 9764780 — intervention group
Group type: EXPERIMENTAL
Intervention: pVL nadir between 20 and 400 copies/ml
Number of subjects: 104
Study 9764780 — intervention group
Group type: COMPARATOR
Intervention: pVL nadir > 400 copies/ml
Number of subjects: 104
Study 7606150 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 72
Study 7606150 — intervention group
Group type: EXPERIMENTAL
Intervention: SUZI
Number of subjects: 72
Study 3296353 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) treatment for 90 days followed by conversion to azathioprine and prednisolone
Number of subjects: 0
Study 3296353 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (AP) with azathioprine and prednisolone throughout
Number of subjects: 0
Study 30573053 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with everolimus-eluting stents
Number of subjects: 1898
Study 30573053 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1898
Study 26198573 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) program Respecting Choices® in addition to usual care
Number of subjects: 0
Study 26198573 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 23799692 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed low-literacy informational patient flyer
Number of subjects: 303
Study 23799692 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 303
Study 22248893 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal block
Number of subjects: 85
Study 22248893 — intervention group
Group type: COMPARATOR
Intervention: Penile block
Number of subjects: 85
Study 17935920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of 1 ml methylprednisolone (40 mg/ml), 0.5 ml Lidocaine (5mg/ml), and 0.15 ml gadolinium (Omniscan 0.5 mmol/ml) into the wrist joint.
Number of subjects: 17
Study 16551888 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% succinylated gelatin
Number of subjects: 45
Study 16551888 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch
Number of subjects: 45
Study 16551888 — intervention group
Group type: COMPARATOR
Intervention: 4% albumin
Number of subjects: 45
Study 12765810 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (rectal temperature 32.0 to 35.0 degrees C)
Number of subjects: 396
Study 12765810 — intervention group
Group type: COMPARATOR
Intervention: Control group (rectal temperature 36.5 to 37.0 degrees C)
Number of subjects: 396
Study 10834773 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine (100 mg hyperbaric)
Number of subjects: 70
Study 10834773 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (50 mg hyperbaric)
Number of subjects: 70
Study 9327671 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav
Number of subjects: 619
Study 9327671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619
Study 8226001 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 19
Study 8226001 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 19
Study 8226001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8226001 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol and Propranolol
Number of subjects: 19
Study 3814678 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 0
Study 3814678 — intervention group
Group type: EXPERIMENTAL
Intervention: Right unilateral ECT
Number of subjects: 0
Study 3814678 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT
Number of subjects: 0
Study 29671079 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based decision aid informing about PSA testing advantages and disadvantages
Number of subjects: 50000
Study 29671079 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic screening
Number of subjects: 50000
Study 29671079 — intervention group
Group type: COMPARATOR
Intervention: General practices
Number of subjects: 50000
Study 29671079 — intervention group
Group type: COMPARATOR
Intervention: Urological practices
Number of subjects: 50000
Study 27824753 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg given 1 hour before IUD insertion
Number of subjects: 118
Study 27824753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 27824753 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg
Number of subjects: 118
Study 24976224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (continuous infusion for 24 hours)
Number of subjects: 111
Study 24976224 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control, continuous infusion for 24 hours)
Number of subjects: 111
Study 22313793 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (3 g/d) and kinako (29 g/d)
Number of subjects: 65
Study 22313793 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 65
Study 22313793 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinako (29 g/d)
Number of subjects: 65
Study 22313793 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (3 g/d)
Number of subjects: 65
Study 20886793 — intervention group
Group type: EXPERIMENTAL
Intervention: Sticking needle and traction method on three points of the mouth (Dicang, Kouheliao, Jiachengjiang)
Number of subjects: 101
Study 20886793 — intervention group
Group type: COMPARATOR
Intervention: Routine needling technique
Number of subjects: 101
Study 18262705 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 62
Study 18262705 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 62
Study 18262705 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 62
Study 16871058 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 16
Study 16871058 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia with morphine (PCA)
Number of subjects: 16
Study 14627879 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 94
Study 14627879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 10696629 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids (5.4 g/d)
Number of subjects: 10
Study 10696629 — intervention group
Group type: COMPARATOR
Intervention: sulfasalazine (2 g/d)
Number of subjects: 10
Study 9356106 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural saline injection (10 mL) at L2‐3 or L3‐4 interspace 10 min after spinal anesthesia
Number of subjects: 20
Study 9356106 — intervention group
Group type: COMPARATOR
Intervention: No epidural saline injection (Control group)
Number of subjects: 20
Study 8210973 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 29
Study 8210973 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil
Number of subjects: 29
Study 8210973 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 29
Study 8210973 — intervention group
Group type: COMPARATOR
Intervention: Control (no oil supplementation)
Number of subjects: 29
Study 2871010 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate 5 mg every 2 weeks
Number of subjects: 0
Study 2871010 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine 5 mg daily
Number of subjects: 0
Study 2871010 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 20 mg daily
Number of subjects: 0
Study 2871010 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of antipsychotic drugs
Number of subjects: 0
Study 31847348 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) - intermittent use formulation (gum, sprays, inhaler)
Number of subjects: 0
Study 31847348 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Nicotine Delivery Systems (ENDS)
Number of subjects: 0
Study 31847348 — intervention group
Group type: COMPARATOR
Intervention: Traditional tobacco smoking
Number of subjects: 0
Study 28871428 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal Doppler-guided hemorrhoidal dearterialization with mucopexy (DM)
Number of subjects: 44
Study 28871428 — intervention group
Group type: COMPARATOR
Intervention: Hemorrhoidectomy using an ultrasonic scalpel (US)
Number of subjects: 44
Study 24891337 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO treatment strategy
Number of subjects: 63
Study 24891337 — intervention group
Group type: COMPARATOR
Intervention: Control (symptoms-based management)
Number of subjects: 63
Study 23243246 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea protein isolates (PPI) included at 25% as the sole source of amino acids (AA)
Number of subjects: 396
Study 23243246 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat-corn distillers dried grains with solubles (wcDDGS) included at 47.7% combined with 51% wheat
Number of subjects: 396
Study 23243246 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-season corn included at 47.7% combined with 51% wheat
Number of subjects: 396
Study 23243246 — intervention group
Group type: COMPARATOR
Intervention: Reference wheat included in all experiments
Number of subjects: 396
Study 21276681 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair (EVAR)
Number of subjects: 299
Study 21276681 — intervention group
Group type: COMPARATOR
Intervention: Open surgical repair (OSR)
Number of subjects: 299
Study 19077924 — intervention group
Group type: EXPERIMENTAL
Intervention: Braced group
Number of subjects: 257
Study 19077924 — intervention group
Group type: COMPARATOR
Intervention: Nonbraced group
Number of subjects: 257
Study 16740530 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating pressure mattress
Number of subjects: 1972
Study 16740530 — intervention group
Group type: COMPARATOR
Intervention: Alternating pressure overlay
Number of subjects: 1972
Study 15546454 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic disease management programme (INT)
Number of subjects: 135
Study 15546454 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (CON)
Number of subjects: 135
Study 11522558 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated carbonated beverages (2 types)
Number of subjects: 0
Study 11522558 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-caffeinated carbonated beverages (2 types)
Number of subjects: 0
Study 11522558 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid without caffeine
Number of subjects: 0
Study 11522558 — intervention group
Group type: COMPARATOR
Intervention: Water (neutral control)
Number of subjects: 0
Study 11522558 — intervention group
Group type: EXPERIMENTAL
Intervention: Skim or chocolate milk (positive control)
Number of subjects: 0
Study 9116952 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdiaphragmatic instillation of bupivacaine
Number of subjects: 0
Study 9116952 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8343321 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoesophageal atrial pacing (TAP)
Number of subjects: 21
Study 8343321 — intervention group
Group type: COMPARATOR
Intervention: Direct current cardioversion (DCC)
Number of subjects: 21
Study 3759779 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback hyperventilation (to increase pH by 0.08‐0.10 at each work load)
Number of subjects: 8
Study 3759779 — intervention group
Group type: COMPARATOR
Intervention: Hyperventilation following acetazolamide (which returned pH to control values)
Number of subjects: 8
Study 3759779 — intervention group
Group type: COMPARATOR
Intervention: Metabolic acidosis induced by acetazolamide (with spontaneous ventilation)
Number of subjects: 8
Study 30846617 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal gratitude
Number of subjects: 43
Study 30846617 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert gratitude
Number of subjects: 43
Study 30846617 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined maternal and expert gratitude
Number of subjects: 43
Study 30846617 — intervention group
Group type: COMPARATOR
Intervention: Control (neutral statements)
Number of subjects: 43
Study 28646977 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjoint Behavioral Consultation (CBC)
Number of subjects: 267
Study 28646977 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 267
Study 25453443 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 1713
Study 25453443 — intervention group
Group type: COMPARATOR
Intervention: Endarterectomy
Number of subjects: 1713
Study 25453443 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting and Endarterectomy
Number of subjects: 1713
Study 22990526 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 30
Study 22990526 — intervention group
Group type: COMPARATOR
Intervention: Normal ventilation
Number of subjects: 30
Study 22990526 — intervention group
Group type: COMPARATOR
Intervention: Hypoventilation
Number of subjects: 30
Study 22168267 — intervention group
Group type: EXPERIMENTAL
Intervention: PLUS (3‐month mobile phone and pedometer based physical activity intervention and 6‐month mobile phone diary maintenance intervention)
Number of subjects: 192
Study 22168267 — intervention group
Group type: EXPERIMENTAL
Intervention: REGULAR (3‐month mobile phone and pedometer based physical activity intervention and 6‐month pedometer maintenance intervention)
Number of subjects: 192
Study 22168267 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (pedometer only, but no intervention will be conducted)
Number of subjects: 192
Study 20391859 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct person‐to‐person prayer intervention (six weekly 1-hour sessions)
Number of subjects: 0
Study 20391859 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prayer sessions)
Number of subjects: 0
Study 16968235 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV‐1 shedding during the vesicle/ulcer stage
Number of subjects: 30
Study 16968235 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV‐1 shedding during clinical stage
Number of subjects: 30
Study 16968235 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV‐1 shedding during subclinical stage
Number of subjects: 30
Study 16968235 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean duration of HSV‐1 shedding
Number of subjects: 30
Study 16968235 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall detection of HSV‐1
Number of subjects: 30
Study 16968235 — intervention group
Group type: EXPERIMENTAL
Intervention: Average log DNA copy number/ml during clinical stage
Number of subjects: 30
Study 16968235 — intervention group
Group type: EXPERIMENTAL
Intervention: Average log DNA copy number/ml during subclinical stage
Number of subjects: 30
Study 14717059 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet high in monounsaturated fat
Number of subjects: 34
Study 14717059 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate‐rich diet
Number of subjects: 34
Study 14717059 — intervention group
Group type: COMPARATOR
Intervention: Saturated fat diet
Number of subjects: 34
Study 11020685 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Number of subjects: 0
Study 11020685 — intervention group
Group type: COMPARATOR
Intervention: Bag-valve-mask ventilation
Number of subjects: 0
Study 11020685 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on paramedic airway management skills
Number of subjects: 0
Study 11020685 — intervention group
Group type: EXPERIMENTAL
Intervention: Costs of training and retraining
Number of subjects: 0
Study 8801151 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha (20 mg in 20 ml normal saline)
Number of subjects: 28
Study 8801151 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (30 IU in 20 ml normal saline)
Number of subjects: 28
Study 8801151 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (20 ml)
Number of subjects: 28
Study 8801151 — intervention group
Group type: COMPARATOR
Intervention: Manual removal of retained placenta (control group)
Number of subjects: 28
Study 1325772 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha h‐ANP (99‐126), 25 micrograms intravenously followed by infusion of 0.1 microgram kg‐1 min‐1
Number of subjects: 8
Study 1325772 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 8
Study 6095372 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus misonidazole (MIS)
Number of subjects: 62
Study 6095372 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 62
Study 31600368 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 236
Study 31600368 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 236
Study 30497132 — intervention group
Group type: EXPERIMENTAL
Intervention: Depomedrol (DEPO) - 1 ml (80 mg) applied directly to the surgical site
Number of subjects: 93
Study 30497132 — intervention group
Group type: COMPARATOR
Intervention: No Depomedrol (NODEPO) - 1 ml saline on Gelfoam carrier
Number of subjects: 93
Study 30497132 — intervention group
Group type: EXPERIMENTAL
Intervention: Depomedrol (DEPO)
Number of subjects: 93
Study 30497132 — intervention group
Group type: COMPARATOR
Intervention: No Depomedrol (NODEPO)
Number of subjects: 93
Study 25958237 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPAS
Number of subjects: 1563
Study 25958237 — intervention group
Group type: EXPERIMENTAL
Intervention: ¡Cuídate!
Number of subjects: 1563
Study 25958237 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1563
Study 24758565 — intervention group
Group type: EXPERIMENTAL
Intervention: DIMS0150 (30 mg rectal administration)
Number of subjects: 34
Study 24758565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 24758565 — intervention group
Group type: EXPERIMENTAL
Intervention: DIMS0150
Number of subjects: 34
Study 22487805 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake flexible fiberoptic intubation (FFI)
Number of subjects: 93
Study 22487805 — intervention group
Group type: COMPARATOR
Intervention: Awake McGrath® video laryngoscope (MVL)
Number of subjects: 93
Study 20199827 — intervention group
Group type: EXPERIMENTAL
Intervention: LC n‐3 PUFA‐rich meal
Number of subjects: 25
Study 20199827 — intervention group
Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 25
Study 17875241 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil 5‐20 microg powder for injection
Number of subjects: 187
Study 17875241 — intervention group
Group type: COMPARATOR
Intervention: Vasoactive intestinal polypeptide (VIP) and phentolamine
Number of subjects: 187
Study 17875241 — intervention group
Group type: COMPARATOR
Intervention: VIP/phentolamine (ampoule)
Number of subjects: 187
Study 17875241 — intervention group
Group type: COMPARATOR
Intervention: VIP/phentolamine (auto-injector)
Number of subjects: 187
Study 16076378 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g sevelamer hydrochloride + 3 g calcium bicarbonate (CaCO3)
Number of subjects: 46
Study 16076378 — intervention group
Group type: COMPARATOR
Intervention: 3 g calcium bicarbonate (CaCO3) alone
Number of subjects: 46
Study 12132060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.375%
Number of subjects: 30
Study 12132060 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.125% plus sufentanil 0.5 microg/mL
Number of subjects: 30
Study 10573104 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 30 mg/day orally for 2 years
Number of subjects: 594
Study 10573104 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 30 mg/day orally for 2 years + UFT 300 mg/day orally for 2 years
Number of subjects: 594
Study 10573104 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT 300 mg/day orally for 2 years
Number of subjects: 594
Study 10573104 — intervention group
Group type: COMPARATOR
Intervention: UFT 300 mg/day orally for 2 years + Tamoxifen (TAM) 30 mg/day
Number of subjects: 594
Study 10573104 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of MMC, TAM, and UFT
Number of subjects: 594
Study 8692031 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO trial (150-g x L(‐1) CHO solution)
Number of subjects: 9
Study 8692031 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO + MCT trial (70 energy% CHO-30 en% MCT suspension containing 29 g MCT)
Number of subjects: 9
Study 8692031 — intervention group
Group type: EXPERIMENTAL
Intervention: HCHO + MCT trial (150-g x L(‐1) CHO solution plus 20 g MCT)
Number of subjects: 9
Study 8692031 — intervention group
Group type: COMPARATOR
Intervention: Control trial (13C-background control trial)
Number of subjects: 9
Study 8692031 — intervention group
Group type: EXPERIMENTAL
Intervention: All trials
Number of subjects: 9
Study 8692031 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT ingestion
Number of subjects: 9
Study 1858990 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of atropine and 50 mg of meperidine plus oral placebo (n = 14)
Number of subjects: 42
Study 1858990 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of oral diazepam and intramuscular placebo (2 mL NaCl, concentration = 0.9) (n = 14)
Number of subjects: 42
Study 1858990 — intervention group
Group type: COMPARATOR
Intervention: Oral and intramuscular placebo (n = 14)
Number of subjects: 42
Study 6356965 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (topically administered glucocorticoid) for 1 week
Number of subjects: 11
Study 6356965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11